Vascular endothelial growth factor (VEGF) is an endothelium-specific secreted protein that induces vasodilation and increases endothelial release of nitric oxide (NO). NO is also reported to modulate leukocyte-endothelium interaction. Therefore, we hypothesized that VEGF might inhibit leukocyte-endothelium interaction via increased release of NO from the vascular endothelium. We used intravital microscopy of the rat mesenteric microcirculation to measure leukocyte-endothelium interactions 2, 4, and 24 h after systemic administration of VEGF to the rat (120 g/kg, i.v., bolus). Superfusion of the rat mesentery with either 0.5 U/ml thrombin or 50 M L-NAME consistently increased the number of rolling, adhering, and transmigrated leukocytes (P<0.01 vs. control mesenteries superfused with Krebs-Henseleit buffer). At 4 and 24 h posttreatment, VEGF significantly attenuated thrombin-induced and L-NAME-induced leukocyte rolling, adherence, and transmigration in rat mesenteric venules. In addition, adherence of isolated rat PMNs to thrombin-stimulated mesenteric artery segments in vitro was significantly reduced in mesenteric arteries isolated from VEGF-treated rats (P<0.001 vs. control rats). Direct measurement of NO demonstrated a threefold increase in basal NO release from aortic tissue of rats injected with VEGF, at 4 and 24 h posttreatment (P<0.01 vs. aortic tissue from control rats). Finally, systemic administration of VEGF to ecNOS-deficient mice failed to inhibit leukocyteendothelium interactions observed in peri-intestinal venules. We concluded that VEGF is a potent inhibitor of leukocyte-endothelium interaction, and this effect is specifically correlated to augmentation of NO release from the vascular endothelium.-Scalia, R., Booth, G., Lefer, D. J. Vascular endothelial growth factor attenuates leukocyte-endothelium interaction during acute endothelial dysfunction: essential role of endothelium-derived nitric oxide.
Vascular endothelium growth factor (VEGF)
2 is a soluble 46 kDa, angiogenic glycoprotein that exerts its biological function through high-affinity tyrosine kinase receptors (1) . Besides its involvement in vascular development, VEGF has been shown to induce endothelium-dependent vasodilation that is accompanied by a decrease in mean arterial blood pressure and tachycardia (2) . The VEGF-induced vasodilation and its effect on vascular permeability are inhibited by nitric oxide (NO) synthase inhibitors (3). Brock et al. (4) demonstrated that VEGF increases cytosolic calcium, which is known to promote calmodulin binding to the endothelial isoform of nitric oxide synthase (NOS) and stimulate NO production (5) . Similarly, VEGF has been shown to increase NO release in bovine (6) , rabbit (7) , and human endothelial cells (8) . More recently, this effect of VEGF on NO production has been associated with upregulation of endothelial cell nitric oxide synthase (ecNOS) activity (9) .
A widely accepted feature of physiological concentrations of NO is its protective role in several models of inflammation, including ischemia-reperfusion and hypercholesterolemia (10 -13) . Several authors have reported that impaired release of NO from ischemic-reperfused vascular beds results in increased leukocyte-endothelium interaction via up- 2 Abbreviations: ANOVA, analysis of variance; ecNOS, endothelial cell nitric oxide synthase; i.p., intraperitoneally; i.v., intravenous; L-NAME, N G -nitro L-arginine methyl ester; NO, nitric oxide; NOS, nitric oxide synthase, PMNs, isolated neutrophiles; SMA, superior mesenteric artery; VEGF, vascular endothelium growth factor. regulation of endothelial cell adhesion molecules (14 -16) . Similarly, systemic administration of NO donors to hypercholesterolemic animals preserves endothelial function and attenuates pathological interactions between circulating leukocytes and the vascular endothelium (13) . Under these conditions, numerous leukocytes adhere to the vascular endothelium and some transmigrate, thus potentiating endothelial dysfunction and tissue injury (17, 18) .
Therefore, the purpose of this study was to examine the effect of VEGF on leukocyte-endothelium interaction in vivo. Using intravital microscopy of the rat mesenteric microcirculation, we illustrated that systemic administration of VEGF inhibits leukocyteendothelium interaction induced by either thrombin or L-NAME (N G -nitro L-arginine methyl ester). This protective effect of VEGF was associated with enhanced release of nitric oxide from the aortic endothelium. Furthermore, we showed a lack of VEGF effect on leukocyte-endothelium interaction in mice missing the gene codifying for ecNOS, thus demonstrating the essential role of ecNOS-generated NO in mediating VEGF action. Taken together, our data suggest a novel role for VEGF in acute inflammatory disorders of the vasculature. These data also may explain the mechanism of the protective effect of VEGF in acute vascular pathologies reported by other investigators (19) .
MATERIALS AND METHODS
This study was performed in accordance with the National Institute of Health guidelines for the use of experimental animals, and all animal protocols were approved by the Institutional Animal Care and Use Committee of Thomas Jefferson University.
Vascular endothelial growth factor
A nonglycosylated form of the human recombinant VEGF (D9836AX-G143AB) was generously supplied by Genentech Inc. (South San Francisco, California). Each animal received a single administration of VEGF protein at a dose of 120 g/kg, as an intravenous (i.v.) bolus. Preliminary studies have shown that the i.v. infusion of 120 g/kg VEGF or injection of vehicle alone (400 l 0.9% saline) does not affect mean arterial blood pressure, heart rate, or cardiac output (20) .
Animal models and study protocols used for intravital microscopy

Rats
Male Sprague-Dawley rats, weighing 250 -275 g, were anesthetized with sodium pentobarbital (65 mg/kg) injected intraperitoneally (i.p.). A tracheotomy was performed to maintain a patent airway throughout the experiment. A PE-50 polyethylene catheter was inserted in the left carotid artery for monitoring mean arterial blood pressure and infusion of anesthetic. The abdominal cavity was opened via a midline laparotomy and a loop of ileal mesentery was exteriorized for observation of the mesenteric microcirculation via intravital microscopy. Rats were randomly divided into one of five groups: 1) rats given VEGF (120 g⅐kg -1 ⅐i.v. bolus -1 ) and superfused with Krebs-Henseleit (K-H) buffer, 2) rats given 0.9% saline and superfused with 50 M L-NAME, 3) rats given 0.9% saline and superfused with 0.5 U/ml thrombin, 4) rats given VEGF and superfused with 50 M L-NAME, and 5) rats given VEGF and superfused with 0.5 U/ml thrombin. Intravital microscopy experiments were performed 2, 4, and 24 h after administration of VEGF. Therefore, five experimental groups were completed for rats injected with VEGF 2, 4, or 24 h before intravital microscopy except the control group, which was studied only at the 4 h time point. The sublingual vein was used for VEGF administration in rats.
Gene-targeted mice
Wild-type (C57BL/6) mice and ecNOS-deficient (ecNOS -/-) mice (C57BL/6; Jackson Laboratories, Bar Harbor, Maine) were anesthetized with sodium pentobarbital (120 mg/kg) injected i.p. The left carotid artery was cannulated for continuous blood pressure monitoring. Intravital microscopy was performed on mouse peri-intestinal venules after exteriorization of a loop of ileal tissue via a midline laparotomy. Mice were randomly divided into one of five groups: 1) wild-type mice given 120 g/kg VEGF and superfused with K-H buffer, 2) wild-type mice given 0.9% saline and superfused with 50 M L-NAME; 3) wild-type mice given 120 g/kg i.v. VEGF and superfused with L-NAME, 4) ecNOS -/-mice given 0.9% saline and superfused with K-H, or 5) ecNOS -/-mice given 120-mg/(kg/i.v. bolus VEGF) and superfused with K-H. Experiments in VEGF-injected mice were performed 4 h after administration of VEGF. The mouse tail vein was used to administer VEGF in mice.
Intravital microscopy recordings
Intravital microscopy of rat mesenteric tissue and mouse peri-intestinal venules was performed according to a previously described method (21) . Briefly, the ileum and mesentery of anesthetized animals were placed in a temperaturecontrolled Plexiglas chamber. A modified K-H solution alone or a K-H solution containing either 50 M L-NAME or 0.5 U/ml thrombin was used to superfuse the rat mesentery and the mouse intestine. A Microphot microscope (Nikon Corp., Tokyo, Japan) was used to visualize both the mesenteric venules in the rat and peri-intestinal venules in the mouse. The image was projected by a high-resolution color video camera (DC-330, DAGE-MTI, Inc., Michigan City, Ind.) onto a color Sony high-resolution video monitor (Multiscan 200-sf) and the image was recorded with a videocassette recorder. All images were then analyzed using computerized imaging software (Phase 3 Image System, Media Cybernetics) on a Pentium-based IBM-compatible computer (Micron Millenia Mxe, Micron Electronics Inc, Nampa, Idaho). Red blood cell velocity was determined on-line using an optical Doppler velocimeter (22) . Red blood cell velocity (V) and venular diameter (D) were used to calculate venular wall shear rate (g), using the formula g ϭ 8 (Vmean/D) (Vmean ϭ Vrbc/ 1.6), where Vϭvelocity and Dϭdiameter (23) . Leukocytes were considered to be rolling if they were moving at a velocity significantly slower than that of red blood cells. A leukocyte was judged to be adherent if it remained stationary for more than 30 s. Adherence is expressed as the number of leukocytes adhering to the endothelium/100 M of vessel length. The number of extravasated leukocytes in the rat mesenteric tissue was counted in the tissue area adjacent to the postcap-illary venules and normalized with respect to area (20 ϫ 100 M).
In vitro adherence of isolated neutrophils (PMNs) to rat superior mesenteric artery endothelium
Immediately after intravital microscopy observations were completed, the superior mesenteric artery (SMA) was rapidly removed from three rats in each of the five experimental groups and placed into warmed oxygenated K-H solution. Fat and connective tissue were removed from SMA segments, which were cut into rings 2 mm in length. Each ring was then opened and placed with the endothelial surface up in a cell culture dish filled with 3 ml of oxygenated K-H solution at 37°C, pH 7.4. Neutrophils were isolated from donor rats according to the method of Williams et al. (24) using the hetastarch exchange transfusion technique. Isolated PMNs (400,000/ml) were labeled with PKH2, a green fluorescent dye (25) , and added to the dishes. SMA segments were then incubated for additional 30 min in a shaker culture bath at 37°C in one of three different solutions: 1) K-H, 2) K-H with thrombin (2 U/ml), or 3) K-H with thrombin (2 U/ml) and the rat-specific anti-P-selectin antibody, CY1748 (20 g/ml). After the incubation period, the SMA segments were carefully removed, lightly rinsed with K-H solution and placed onto glass microscope slides. Adherent PMNs were counted using epifluorescence microscopy (Nikon, Tokyo, Japan) on five fields from each vessel segment and expressed as numbers of adherent PMNs/mm 2 of endothelial surface area (26) .
Effect of VEGF on NO released from isolated rat aortic segments
We used freshly isolated rat aortic rings as the source of primary endothelial cells. After completion of intravital microscopy recordings, thoracic aortae were rapidly isolated from three rats in each of the five experimental groups and immersed in warm oxygenated K-H solution. Aortas were cleaned of adherent fat and connective tissue, and rings 6 -7 mm in length were carefully prepared. Rings were subsequently cut and opened from randomly selected areas of the aorta and fixed by small pins with the endothelial surface facing up in 24-well culture dishes containing 1 ml K-H solution. After equilibration at 37°C, NO released into the K-H solution was measured. NO was measured according to the method of Guo et al. (27) . Briefly, a NO meter (Iso-NO, World Precision Instruments, Inc., Sarasota, Fla.) connected to a polarographic NO electrode was used. The model of the NO electrode we used was internally shielded to minimize external electrical interference. Calibration of the NO electrode was performed daily before each experimental protocol. Standard calibration curve was obtained by graded concentrations of KNO 2 at 0, 5, 10, 25, 50, 100, 250, and 500 nM (final concentrations) into a calibration solution containing 0.1 M KI and 0.1 M H 2 SO 4 .
Data analysis
All data are presented as means Ϯ se. Data were compared by analysis of variance (ANOVA) using post hoc analysis with Fisher's corrected t test. All data on leukocyte rolling, adherence, transmigration, arterial blood pressure, and shear rates were analyzed by ANOVA, incorporating repeated measurements. Probabilities of 0.05 or less were considered statistically significant.
RESULTS
Intravital microscopy
Rat mesentery
Data for leukocyte rolling, adherence, and transmigration are summarized in Figs. 1-3 . We examined mesenteric venules ranging from 38 Ϯ 4 to 42 Ϯ 3 M in diameter, and there was no difference in venular diameter among any of the groups studied. The venular shear rates were also very similar in all groups, ranging from 587 Ϯ 28 to 613 Ϯ 32 s -1 . Similarly, there was no significant difference in initial mean arterial blood pressures among all groups of rats after all surgical procedures were completed. Mean arterial blood pressures ranged between 145 Ϯ 8 and 154 Ϯ 10 mmHg over the 2 h observation period. In addition, no significant systemic effect was recorded after the exposure of the rat mesentery to either thrombin or L-NAME. These findings clearly indicate that the adhesive interactions observed between circulating leukocytes and the microvascular endothelium were not due to changes in hemodynamics brought about by the superfusion with thrombin or L-NAME or by systemic administration of 120 g/kg recombinant VEGF protein (20) .
Thrombin (0.5 U/ml) markedly increased leukocyte rolling and adherence 60 -120 min after superfusion (Fig. 1) . However, both leukocyte rolling and adherence were virtually abolished in thrombintreated rats given VEGF at 4 and 24 h postinjection (Fig. 1) . Similarly, leukocyte transmigration was significantly increased at 90 -120 min after thrombin stimulation of the mesentery, and this response was attenuated by VEGF treatment at 4 and 24 h postinjection (Fig. 3) . In contrast, administration of VEGF 2 h postinjection failed to inhibit thrombin-stimulated leukocyte rolling, adherence, and transmigration ( Fig. 1 and Fig. 3) .
In parallel experimental studies, we investigated the effects of VEGF treatment on leukocyte rolling, adherence, and transmigration induced by superfusion of the rat mesentery with L-NAME ( Fig. 2 and  Fig. 3) . Superfusion of the mesenteric tissue with 50 M L-NAME increased leukocyte rolling fivefold, leukocyte adherence sevenfold, and leukocyte transmigration sevenfold at 120 min. Systemic administration of VEGF also significantly inhibited the L-NAME-induced increase in leukocyte-endothelium interactions to a degree comparable to its effects on thrombin-stimulated mesenteries. In particular, 4 h after injection of VEGF, leukocyte rolling, adherence, and transmigration induced by L-NAME superfusion were attenuated to 10 Ϯ 4, 2 Ϯ 1 and 4 Ϯ 1, respectively. In addition, L-NAME-induced leukocyte-endothelium interactions were not inhibited at 2 h postinjection, thus confirming that a 4 h lag time is required in vivo for initiating the antiinflammatory activity of VEGF. Therefore, systemic administration of VEGF to the rat is able to inhibit leukocyteendothelium interaction after exposure of the mesenteric microvasculature to both inflammatory stimuli or nitric oxide synthase inhibitors.
In vitro adherence of PMNs to SMA endothelium
Thrombin stimulation of isolated SMA segments isolated from control rats resulted in a marked increase in the adhesion of unstimulated rat PMNs to the SMA endothelium (Fig. 4) . The number of adhered PMNs/mm 2 increased by sevenfold in thrombin-stimulated SMA endothelium as compared to control SMA endothelium (Fig. 4) . However, the adhesion of neutrophils was significantly lower in SMA endothelium obtained from both 4 and 24 h VEGF-injected rats (Fig. 4) . VEGF reduced PMN adhesion to thrombin-stimulated SMA segments by 40% (PϽ0.05 vs. thrombin alone). Comparable results were obtained by coincubation of thrombinstimulated SMA segments with 20 g/ml of an anti-P-selectin monoclonal antibody (Fig. 4) . Thus, systemic administration of VEGF significantly attenuated the adhesion of rat PMNs to thrombin-stimulated superior mesenteric vascular endothelium via a P-selectin mechanism. This clearly demonstrates that systemic administration of VEGF to the rat results in attenuation of leukocyte-endothelium interaction at both the macrovascular and microvascular level. Numbers in parentheses indicate numbers of rats studied. The VEGF protein was administered to the rats at a dose of 120 g/kg, as an i.v. bolus. *PϽ0.05 from control rats superfused with L-NAME and **PϽ0.01 from control rats superfused with L-NAME. 
Effect of VEGF administration on NO release from isolated rat aortic segments
We detected a small basal level of NO release in the range of 35 Ϯ 6 pmol/g of tissue in aortic rings isolated from control rats (Fig. 5) . This basal release of NO was not different in aortic tissue obtained 2 h after VEGF administration to the rats. However, 4 and 24 h after rats were given the bolus dose of VEGF, the basal release of NO measured in aortic rings increased from 35 Ϯ 6 to 110 Ϯ 15 pmol/mg tissue (PϽ0.001). Moreover, the addition of a maximal concentration of L-NAME (i.e., 100 M) inhibited NO release in aortic rings obtained from both control rats and VEGF-treated rats (Fig. 5) . Therefore, systemic administration of recombinant VEGF protein to the rats increases endothelium-derived nitric oxide release in the aorta. This effect begins 4 h after a bolus ejection of VEGF and lasts at least up to 24 h postinjection. In addition, VEGF-induced NO release is likely mediated via stimulation of nitric oxide synthase on the vascular endothelium, as confirmed by its blockade by the NOS-inhibitor L-NAME.
Mouse peri-intestinal venules
To test our hypothesis that ecNOS mediates the attenuation of leukocyte-endothelium interaction in the mesenteric vasculature during acute inflammation, we performed similar experiments in wildtype mice and ecNOS-deficient mice. Compared with C57BL/6 wild-type mice, ecNOS-deficient mice exhibited a higher number of rolling (Fig. 6, upper  panel) and adherent leukocytes (Fig. 6, lower panel) in peri-intestinal venules. Superfusion of the ileal tissue of wild-type mice with 50 M L-NAME increased the number of rolling and adhering leukocytes to 51 Ϯ 4 cells/min and 12 Ϯ 1 cells/100 M, respectively (PϽ0.001 vs. control wild-type mice superfused with K-H buffer). These values were comparable to those observed in ecNOS-deficient mice superfused with only K-H buffer. At 4 h postinjection, VEGF (120 g/kg) consistently attenuated L-NAME-induced leukocyte rolling and adherence in peri-intestinal venules of wild-type mice (data not shown) while failing to inhibit the abnormal increase in baseline leukocyte rolling (Fig. 6, upper panel) and adherence (Fig. 6, lower panel) observed in ecNOS-deficient mice. This clearly demonstrates that up-regulation of ecNOs activity is the predominant, if not the only, mechanism by which VEGF attenuates leukocyte-endothelium interaction in acute model of inflammation. In addition, we found no significant systemic effects on hemodynamics after administration of VEGF to either wild-type or ecNOS-deficient mice. When venular shear rates were calculated in the five experimental groups of mice, no significant difference was recorded despite the higher mean arterial blood pressure values observed in ecNOS-deficient mice as compared to control wild-type mice (MABP 155 Ϯ 15 and 110 Ϯ 8 mmHg, respectively; PϽ0.05). Initial shear rates values were 606 Ϯ 41, 560 Ϯ 31, 555 Ϯ 39, 608 Ϯ 30, and 597 Ϯ 29 s -1 for the five groups of mice. These values were not different from each other and did not change over the 60 min observation period.
DISCUSSION
The major finding in this study is that i.v. administration of a single bolus dose of VEGF attenuates inflammation induced leukocyte-endothelium in- teraction at both microvascular and macrovascular levels. The mechanism of the inhibitory effect of VEGF on leukocyte-endothelium interaction was found to be mediated by endothelium-derived nitric oxide. These conclusion are based on the following observations: 1) VEGF inhibits leukocyte-endothelium interaction in vivo in the splanchnic microvasculature of rats and mice; 2) adhesion of isolated rat PMNs to thrombin-stimulated SMA segments in vitro is significantly attenuated in SMA tissue obtained from VEGF-treated rats; 3) a threefold increase in the basal release of NO occurs in aortic rings obtained from rats injected with VEGF; and 4) deletion of the ecNOS synthase gene (i.e., ecNOS-/-mice) abolishes the VEGF effects on leukocyte-endothelium interaction.
The widespread expression and organ-specific distribution of VEGF messenger RNA and protein in normal rat tissue support the concept that VEGF may play a multifunctional role in the maintenance of normal vascular function in addition to mediating vascular growth (28) . Since Ku and co-workers (29) demonstrated that VEGF stimulates the release of endothelial-derived nitric oxide in canine coronary arteries, several others have shown that VEGF is able to attenuate tissue injury after ischemia-reperfusion of the heart (30), restore endothelial function in balloon-injured arteries (31) , and promote recovery of normal endothelial reactivity of ischemic large arteries (32) . Our results are the first to explain the mechanism of the protective effect of VEGF against inflammatory states of the large conduit arteries, as well as of the microcirculation.
It is well established that NO is a potent modulator of leukocyte adhesion to the vascular endothelium (15, 33) . Previous studies have clearly demonstrated antineutrophil properties of NO in vivo as well as in vitro (11, 15, 34) . In fact, administration of authentic NO (12) , NO donors (11), or the NO precursor L-arginine (35) have all proved to be highly beneficial in a number of inflammatory disease states, including ischemia-reperfusion and hypercholesterolemia (13) . Furthermore, we have recently shown that NO donation inhibits leukocyte-endothelium interactions induced by activation of the microvascular endothelium with both L-NAME (14) or thrombin (18) . In addition, De Caterina et al. (36) have shown that that nitric oxide inhibits the expression of cell adhesion molecules on the vascular endothelium. In this regard, inhibition of adhesion molecule expression is likely to be an essential mechanism of the antileukocytic actions of NO.
Here we provide strong evidence that systemic administration of VEGF is able to attenuate enhanced leukocyte-endothelium interaction induced by inflammatory stimuli via increased release of NO from the vascular endothelium. This result is consistent with earlier findings showing that VEGF up-regulates ec-NOS enzyme, thus eliciting a biphasic stimulation of endothelial NO production (9) . Due to this NO-potentiating property of VEGF, it is likely that after administration of VEGF, increased NO release is responsible for down-regulation of leukocyte-endothelium interactions. Nevertheless, the precise mechanism of this immunomodulatory function of VEGF and how it relates to cell adhesion molecule expression in vivo remain to be determined.
We also obtained evidence that VEGF did not inhibit leukocyte-endothelium interaction in mice lacking the gene encoding for ecNOS enzyme. Experiments performed in the mouse model indicate that ecNOS activity is essential for mediating VEGF actions. In this regard, Murohara et al. (37) have recently shown that in ecNOS-deficient mice angiogenesis is not induced by either recombinant VEGF protein administration or adenovirus-mediated VEGF gene transfer.
In summary, we have demonstrated that a single i.v. dose of VEGF markedly inhibits pathological leukocyte-endothelium interaction 4 and 24 h later in a well-established experimental model of inflammation. In particular, VEGF inhibited leukocyte rolling, adhesion, and transmigration within rat mesenteric venules, attenuated adherence of rat PMNs to isolated rat SMA endothelium, and increased release of nitric oxide from the aortic endothelium. In addition, no VEGF action on leukocyte-endothelium interaction was observed in the absence of ecNOS, as assessed in ecNOSdeficient mice. To our knowledge, this is the first in vivo evidence showing that potentiation of NO release via systemic administration of VEGF results in attenuation of pathological leukocyte recruitment in inflamed vascular areas. Since inhibition of leukocyte-endothelium interaction has been found to be beneficial in several pathophysiological states of the cardiovascular system, this effect may be important in understanding the role of VEGF therapy in cardiovascular diseases, including ischemia-reperfusion injury and atherosclerosis. 
